- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Interview Highlights from the SNMMI 2023 Conference
Catch up on recent interviews with Jeremie Calais, M.D. MSc, Krishna Patel, M.D., Phillip Kuo, M.D. Ph.D, and more faculty from the Society for Nuclear Medicine and Molecular Imaging (SNMMI) 2023 conference.
Whether it was strategies to address the workforce pipeline in nuclear medicine, emerging insights on positron emission tomography (PET) in the management of prostate cancer and new research on the imaging of clear cell renal cell carcinoma, we learned quite a bit during on-site interviews at the Society of Nuclear Imaging and Molecular Imaging (SNMMI) 2023 conference in Chicago. Review the slideshow below to check out some of our on-site interviews from the conference.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
